William T. Symonds

Biography

 Dr. William T. Symonds III, also known as Bill, Pharmd. has been the Chief Development Officer of Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) since 2015. Dr. Symonds has been Senior Vice President of Clinical Research at Roivant Sciences, Inc., since May 2014. Prior to that, he served as Vice-President of Liver Disease Therapeutic Area at Gilead Sciences, Inc. from February 2012 to April 2014. He served as Senior Vice President at Pharmasset, Inc. He served as a Vice President of Clinical Pharmacology of Gilead Pharmasset LLC from January 24, 2007 to January 2012. He served as Senior Advisor of OnCore since November 2014. From 1993 to 2007, he held various positions of increasing responsibility at GlaxoSmithKline, most recently as Director, Antiviral Clinical Pharmacology and Discovery Medicine. He Led the development of compounds for hepatitis B virus and hepatitis C virus infection, most notably Sovaldi® for hepatitis C and Contributed to new drug approvals for Ziagen®, Agenerase®, and Epzicom during his 15-year tenure at GlaxoSmithKline. He is a seasoned drug development professional with extensive experience in the clinical development of multiple new drug candidates from phase 1 to phase 4. He has been an Executive Director of Arbutus Biopharma Corporation since March 4, 2015. He served as a Director of OnCore Biopharma, Inc. since August 2014. Dr. Symonds received his Doctorate of Pharmacy from Campbell University in North Carolina and he completed a Fellowship in Clinical Pharmacokinetics focusing on anti-infective pharmacology at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York.

Research Interest

 Bioinformatics and Biopharma